The Absolute Effect / Evidence index
Supportive / Treatment Toxicity · Phase III double-blind placebo-controlled; N=165 with persistent CIT in GI cancers. Romiplostim vs placebo for three chemotherapy cycles. Primary endpoint: no CIT-related chemotherapy dose modification in cycles 2 and 3. · No dose modification: 84% (92/109) vs 36% (20/56)
RECITE
Clinical question: Does romiplostim prevent chemotherapy dose modifications in patients with persistent chemotherapy-induced thrombocytopenia?
No dose modification: 84% (92/109) vs 36% (20/56); OR 10.16 (95% CI 4.44–23.72; P<0.001). Absolute gain 48 points; NNT 3. · Registry:
Design, population and treatment
Phase III double-blind placebo-controlled; N=165 with persistent CIT in GI cancers. Romiplostim vs placebo for three chemotherapy cycles. Primary endpoint: no CIT-related chemotherapy dose modification in cycles 2 and 3.
Key efficacy outcome
Grade ≥3 AEs 37% vs 22% (descriptive NNH 7); thromboembolic events 2% vs 0%. Drug-attributed events uncommon.
Safety and absolute effect
No CIT-related dose modification (%)
https://www.nejm.org/doi/10.1056/NEJMoa2511882
Interpretation and limitations
Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.